免疫治疗在胃癌新辅助治疗中的研究进展  

Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer

作　　者：陈博晋 胡星怡 赵菁文 郑爱红[2] CHEN Bojin;HU Xingyi;ZHAO Jingwen;ZHENG Aihong(The Second Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310014,China;Department of Oncology Center,Zhejiang Provincial People’s Hospital,Affiliated People’s Hospital,Hangzhou Medical College,Hangzhou 310014,China)

机构地区：[1]浙江中医药大学第二临床医学院,杭州310014 [2]浙江省人民医院,杭州医学院附属人民医院肿瘤中心(肿瘤内科),杭州310014

出　　处：《肿瘤防治研究》2022年第7期727-732,共6页Cancer Research on Prevention and Treatment

基　　金：浙江省教育厅一般科研项目(A.H.Z.Y202044796)。

摘　　要：胃癌(GC)在我国发病的重要特点是中晚期确诊病例占确诊人数的大多数,早期诊断的患者不足10%。对于进展期的GC患者来说,标准治疗策略是手术联合术后辅助治疗或者术前新辅助+手术联合术后辅助治疗,而近年来免疫治疗成为一种治疗肿瘤的创新方法。如何在新辅助治疗中最大程度地利用免疫治疗,从而取得更好的临床获益值得探讨。本文综述了免疫治疗在GC新辅助治疗中的研究进展,进一步研究新辅助治疗联合免疫治疗对免疫系统功能的影响将有助于提高对GC的治疗水平。The majority of diagnosed cases of gastric cancer are in the middle and late stages,while less than 10%of patients are diagnosed in the early stages in China.The standard treatment strategy for patients with progressive gastric cancer is surgery combined with postoperative adjuvant therapy or preoperative neoadjuvant followed by surgery combined with postoperative adjuvant therapy.Immunotherapy is now recognized as an innovative approach for cancers.It is worth exploring how to best use immunotherapy in neoadjuvant therapy to achieve better clinical benefit.Therefore,this paper reviews the progress of immunotherapy in neoadjuvant therapy for GC.Further studies and the understanding of immune system function by neoadjuvant therapy combined with immunotherapy will help to improve the treatment of gastric cancer.

关 键 词：胃癌 新辅助治疗 免疫治疗 肿瘤微环境 

分 类 号：R730.58[医药卫生—肿瘤] R735.2[医药卫生—临床医学]